A Plus Biotechnology Co (TPE:6918) Other Long-Term Liabilities: NT$0.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
74 GF Score
Price NT$74.80
GF Value NT$87.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co Other Long-Term Liabilities?

A Plus Biotechnology Co TPE:6918 +0.40% 74 Other Long-Term Liabilities is NT$0.3 Mil as of Jun. 2026. GuruFocus rates TPE:6918 with a GF Score™ of 74/100 and a GF Value™ of NT$87.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

A Plus Biotechnology Co's other long-term liabilities for the quarter that ended in Jun. 2026 was NT$0.3 Mil.

A Plus Biotechnology Co's quarterly other long-term liabilities declined from Dec. 2025 (NT$0.3 Mil) to Mar. 2026 (NT$0.3 Mil) and declined from Mar. 2026 (NT$0.3 Mil) to Jun. 2026 (NT$0.3 Mil).

A Plus Biotechnology Co's annual other long-term liabilities increased from Dec. 2023 (NT$0.9 Mil) to Dec. 2024 (NT$0.9 Mil) but then declined from Dec. 2024 (NT$0.9 Mil) to Dec. 2025 (NT$0.3 Mil).

A Plus Biotechnology Co Other Long-Term Liabilities Related Terms

A Plus Biotechnology Co Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Other Long-Term Liabilities Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 1.16 0.92 0.93 0.94 0.32

A Plus Biotechnology Co Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial 0.54 0.54 0.32 0.32 0.26
TPE:6918
74GF Score
A Plus Biotechnology Co Ltd TPE:6918
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of NT$0.3 Mil mean?
A Plus Biotechnology Co (TPE:6918) has a Other Long-Term Liabilities of NT$0.3 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on A Plus Biotechnology Co and its competitors.
Is A Plus Biotechnology Co's Other Long-Term Liabilities too high?
A Plus Biotechnology Co's current Other Long-Term Liabilities is NT$0.3 Mil. Overall, A Plus Biotechnology Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Other Long-Term Liabilities compare to ABT and SYK?
A Plus Biotechnology Co's Other Long-Term Liabilities of NT$0.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Other Long-Term Liabilities is NT$0.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.17, compared to a current price of NT$74.80 — trading 14.2% below its estimated fair value. The current Other Long-Term Liabilities is NT$0.3 Mil. A Plus Biotechnology Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Other Long-Term Liabilities is NT$0.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$74.80 is trading 14.2% below its estimated GF Value™ of NT$87.17. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • Other Long-Term Liabilities: NT$0.3 Mil
  • GF Value™: NT$87.17 vs. price of NT$74.80 (14.2% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd is a Taiwanese medical device company that develops, manufactures, and sells orthopedic implants and related surgical products. Its portfolio covers trauma and reconstructive applications across the body, including chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and external fixation systems, along with biologics such as bone graft materials. The company serves hospitals, orthopedic surgeons, and healthcare distributors, generating revenue primarily through product sales of implants and instruments. It operates in Taiwan and China, with Taiwan accounting for the majority of its revenue. The company is listed on the Taiwan Stock Exchange under the ticker 6918.
74GF Score

Get the complete analysis for TPE:6918

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.80
Price
NT$87.17
GF Value